1. Home
  2. NYMTG vs RVMDW Comparison

NYMTG vs RVMDW Comparison

Compare NYMTG & RVMDW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NYMTG
  • RVMDW
  • Stock Information
  • Founded
  • NYMTG N/A
  • RVMDW 2014
  • Country
  • NYMTG United States
  • RVMDW United States
  • Employees
  • NYMTG N/A
  • RVMDW N/A
  • Industry
  • NYMTG Real Estate Investment Trusts
  • RVMDW
  • Sector
  • NYMTG Real Estate
  • RVMDW
  • Exchange
  • NYMTG Nasdaq
  • RVMDW Nasdaq
  • Market Cap
  • NYMTG N/A
  • RVMDW N/A
  • IPO Year
  • NYMTG N/A
  • RVMDW N/A
  • Fundamental
  • Price
  • NYMTG $25.25
  • RVMDW $0.18
  • Analyst Decision
  • NYMTG
  • RVMDW
  • Analyst Count
  • NYMTG 0
  • RVMDW 0
  • Target Price
  • NYMTG N/A
  • RVMDW N/A
  • AVG Volume (30 Days)
  • NYMTG N/A
  • RVMDW 15.6K
  • Earning Date
  • NYMTG N/A
  • RVMDW 02-26-2025
  • Dividend Yield
  • NYMTG N/A
  • RVMDW N/A
  • EPS Growth
  • NYMTG N/A
  • RVMDW N/A
  • EPS
  • NYMTG N/A
  • RVMDW N/A
  • Revenue
  • NYMTG N/A
  • RVMDW $742,000.00
  • Revenue This Year
  • NYMTG N/A
  • RVMDW N/A
  • Revenue Next Year
  • NYMTG N/A
  • RVMDW N/A
  • P/E Ratio
  • NYMTG N/A
  • RVMDW N/A
  • Revenue Growth
  • NYMTG N/A
  • RVMDW N/A
  • 52 Week Low
  • NYMTG N/A
  • RVMDW $0.10
  • 52 Week High
  • NYMTG N/A
  • RVMDW $0.12
  • Technical
  • Relative Strength Index (RSI)
  • NYMTG N/A
  • RVMDW N/A
  • Support Level
  • NYMTG N/A
  • RVMDW N/A
  • Resistance Level
  • NYMTG N/A
  • RVMDW N/A
  • Average True Range (ATR)
  • NYMTG 0.00
  • RVMDW 0.00
  • MACD
  • NYMTG 0.00
  • RVMDW 0.00
  • Stochastic Oscillator
  • NYMTG 0.00
  • RVMDW 0.00

About RVMDW Revolution Medicines Inc. Warrant

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Share on Social Networks: